Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 785 across all filing types
Latest filing 2025-11-11 Interim / Quarterly Rep…
Country SE Sweden
Listing ST MOB

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – September 2025' for Moberg Pharma AB. It contains detailed financial data for the nine-month and third-quarter periods, including net revenue, EBITDA, EBIT, profit for the period, and earnings per share. It also includes management commentary, business updates, and operational highlights. Since it provides comprehensive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2025
2025-11-11 English
Moberg Pharma och Karo Healthcare ingår exklusivt licensavtal för MOB-015/Terclara i Europa, vilket driver tillväxt och marknadsexpansion
M&A Activity Classification · 100% confidence The document is a press release announcing a new exclusive licensing agreement between Moberg Pharma and Karo Healthcare for the commercialization of a pharmaceutical product (MOB-015/Terclara) in Europe. This type of strategic partnership announcement, which details business expansion and commercial strategy, falls under the category of general regulatory announcements or corporate news that does not fit into specific financial reporting categories like 10-K or Earnings Releases. Given the nature of the announcement as a corporate update regarding a business agreement, it is classified as a Regulatory Filing (RNS).
2025-11-05 Swedish
Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential
M&A Activity Classification · 100% confidence The document is a press release announcing an exclusive licensing agreement between Moberg Pharma and Karo Healthcare for the commercialization of a pharmaceutical product (MOB-015/Terclara) in Europe. This type of corporate development, specifically regarding partnerships and commercial expansion, falls under the category of M&A Activity (TAR) as it relates to strategic business agreements and licensing deals.
2025-11-05 English
Moberg Pharma’s Nomination Committee appointed
Board/Management Information Classification · 100% confidence The document is a press release announcing the formation and composition of the company's Nomination Committee for the upcoming Annual General Meeting. It details the members of the committee, their shareholding representation, and the process for submitting proposals. This type of corporate governance announcement regarding board-related committees does not fit into specific categories like 'Board/Management Information' (which usually refers to changes in personnel) or 'Proxy Solicitation' (which is a formal request for votes). As it is a general regulatory announcement regarding corporate governance structure, it falls under the 'Regulatory Filings' (RNS) category.
2025-10-31 English
Moberg Pharmas valberedning utsedd
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of the Nomination Committee (valberedning) for Moberg Pharma. This type of announcement relates to corporate governance and the preparation for the upcoming Annual General Meeting. Since it does not fit into specific categories like financial reports, dividends, or director dealings, and is a standard regulatory announcement regarding company governance structure, it is classified as a Regulatory Filing (RNS).
2025-10-31 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a formal notification of a change in shareholding (flaggningsmeddelande) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a transaction by Skandinaviska Enskilda Banken AB (publ) in Moberg Pharma AB, resulting in their ownership falling below the 5% threshold. This fits the definition of a Major Shareholding Notification (MRQ).
2025-10-07 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.